ADV7103: An Investigational Drug Designed to Treat Distal Renal Tubular Acidosis (dRTA) – Global Emerging Insight and Market Forecast 2017-2020 & 2021-2030 – ResearchAndMarkets.com

ADV7103: An Investigational Drug Designed to Treat Distal Renal Tubular Acidosis (dRTA) – Global Emerging Insight and Market Forecast 2017-2020 & 2021-2030 – ResearchAndMarkets.com




ADV7103: An Investigational Drug Designed to Treat Distal Renal Tubular Acidosis (dRTA) – Global Emerging Insight and Market Forecast 2017-2020 & 2021-2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “ADV7103 – Emerging Insight and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.

ADV7103 is an investigational drug designed to treat distal renal tubular acidosis (dRTA) in patients of all ages. ADV7103 is an innovative product with a prolonged-release formulation designed to maintain a sustained release over a 12-hour period, thus allowing for twice-a-day treatment.

The product was developed as a multi-particulate formulation in 2mm granules that contains two active pharmaceutical ingredients. ADV7103 is tasteless and easy to administer orally in patients of all ages. ADV7103 is an investigational drug and has not yet been approved by any regulatory authority and is being developed by Advicenne. Advicenne Received Positive CHMP Opinion Recommending Approval of ADV7103 for the Treatment of Distal Renal Tubular Acidosis (dRTA).

“ADV7103 – Emerging Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Renal tubular acidosis (RTA) in 7 Major Markets. A detailed picture of the ADV7103 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product.

The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Scope of the Report

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around ADV7103.
  • The report contains forecasted sales for ADV7103 till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Renal tubular acidosis (RTA).
  • The report also features the SWOT analysis with analyst insights and key findings of ADV7103.

ADV7103 Analytical Perspective

In-depth ADV7103 Market Assessment

This report provides a detailed market assessment of ADV7103 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

ADV7103 Clinical Assessment

The report provides the clinical trials information of ADV7103 covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

  • In the coming years, the market scenario for Renal tubular acidosis (RTA) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence ADV7103 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Renal tubular acidosis (RTA) are giving market competition to ADV7103 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of ADV7103.
  • This in-depth analysis of the forecasted sales data of ADV7103 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ADV7103.

Key Questions Answered

  • WHICH company is developing ADV7103 along with the phase of the clinical study?
  • What is the technology utilized in the development of ADV7103?
  • What is the product type, route of administration and mechanism of action of ADV7103?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ADV7103 development?
  • What are the key designations that have been granted to ADV7103?
  • What is the forecasted market scenario of ADV7103?
  • What is the history of ADV7103 and what is its future?
  • What is the forecasted sales of ADV7103 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to ADV7103?
  • Which are the late-stage emerging therapies under development for the treatment of the Renal tubular acidosis (RTA)?

Key Topics Covered:

1. Drug Overview

1.1. Product Detail

1.2. Mechanism of Action

1.3. Dosage and Administration

1.4. Research and development activity

1.4.1. Clinical Development

1.4.2. Safety and Efficacy

1.5. Other Development Activities

2. Market Assessment

2.1. 7MM Market Analysis

2.2. The United States Market

2.3. Germany Market

2.4. France Market

2.5. Italy Market

2.6. Spain Market

2.7. United Kingdom Market

2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/iuaybr

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900